<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632225</url>
  </required_header>
  <id_info>
    <org_study_id>VMALS-002-2</org_study_id>
    <nct_id>NCT04632225</nct_id>
  </id_info>
  <brief_title>Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>REViVALS-1A</acronym>
  <official_title>A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helixmith Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helixmith Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of intramuscular (IM) administration of&#xD;
      Engensis in Participants with Amyotrophic Lateral Sclerosis (ALS) as compared to Placebo.&#xD;
      Safety will be assessed by incidences of treatment-emergent adverse events (TEAEs),&#xD;
      treatment-emergent serious adverse events (TESAEs), injection site reactions (ISRs) and other&#xD;
      adverse events of special interest (AESIs), and the clinically significant laboratory values&#xD;
      after injections of Engensis compared to Placebo. Exploratory endpoints include assessment of&#xD;
      muscle function using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale&#xD;
      (ALSFRS-R) and ALSFRS-R subscores for Fine and Gross Motor Function; muscle strength by&#xD;
      quantitative testing using handheld dynamometry (HHD) and the Accurate Test of Limb Isometric&#xD;
      Strength (ATLIS) where available; quality of life using the ALS Assessment Questionnaire&#xD;
      (ALSAQ-40); patient global impression of change (PGIC), clinical global impression of change&#xD;
      (CGIC), and clinical global impression of severity (CGIS); and evaluation of lung function&#xD;
      using Slow Vital Capacity (SVC). Muscle biopsies will be performed during the study for&#xD;
      future biomarker analyses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of intramuscular (IM) injections of Engensis in Participants with Amyotrophic Lateral Sclerosis (ALS) compared to Placebo</measure>
    <time_frame>From the Day 0 Visit to the Day 180 Visit</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) after injections, injection site reactions, and clinically significant laboratory values for Engensis compared to Placebo</description>
  </primary_outcome>
  <other_outcome>
    <measure>Changes in muscle function following Engensis injections compared to Placebo</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>Change from Baseline (Day 0) in total mean Revised Amyotrophic Lateral Sclerosis Function Rating (ALSFRS-R) scores, subscores for Fine and Gross Motor Functions and Bulbar Function, and slope of the total score</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of muscle strength changes following Engensis injections compared to Placebo</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>As assessed bilaterally by Hand-Held Dynamometry (HHD) in muscles in the upper and lower extremities</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of muscle strength changes following Engensis injections compared to Placebo</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>As assessed bilaterally by the Accurate Test of Limb Isometric Strength (ATLIS) where available</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Quality of Life improvement following Engensis injections compared to Placebo</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>As assessed using the ALS Assessment Questionnaire with 40 items (ALSAQ-40)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Patient and Clinical Reported Outcome improvement following Engensis injections compared to Placebo</measure>
    <time_frame>Day 84 to Day 180</time_frame>
    <description>As assessed using the Patient Global Impression of Change (PGIC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Patient and Clinical Reported Outcome improvement following Engensis injections compared to Placebo</measure>
    <time_frame>Day 84 to Day 180</time_frame>
    <description>As assessed using the Clinical Global Impression of Change (CGIC)</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine effects of Engensis on respiratory function compared to Placebo</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>As assessed using Slow Vital Capacity (SVC)</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine effects of Engensis on respiratory function compared to Placebo</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>As assessed by time to tracheostomy</description>
  </other_outcome>
  <other_outcome>
    <measure>To determine effects of Engensis on survival compared to Placebo</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>Time to all-cause mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparing gene expression differences in muscle atrophy biomarkers between subjects receiving Engensis and subjects receiving Placebo by using RNA sequencing</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <description>Using RNA sequencing methods to obtain genome transcription profiles of the group receiving Engensis and the group receiving Placebo, and compare the gene expression differences between these two groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Engensis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engensis</intervention_name>
    <description>Lyophilized biologic to be reconstituted containing Engensis</description>
    <arm_group_label>Engensis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injectable liquid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinically definite or probable Amyotrophic Lateral Sclerosis (ALS) or&#xD;
             laboratory-supported probable ALS as defined in the revised El Escorial/Airlie House&#xD;
             diagnostic criteria&#xD;
&#xD;
          2. The site of onset of ALS symptoms is a limb and experiencing symptoms of lower motor&#xD;
             dysfunction (e.g., weakness, atrophy, cramps, poor circulation, etc.) with upper motor&#xD;
             neuron symptoms (e.g., weakness, brisk reflexes, spasticity)&#xD;
&#xD;
          3. Onset of ALS symptoms ≤ 4 years&#xD;
&#xD;
          4. Slow Vital Capacity (SVC) ≥ 50% of predicted value at Screening&#xD;
&#xD;
          5. Not taking riluzole, or on a stable dose (defined as no noted toxicities) for at least&#xD;
             30 days prior to Screening and throughout the study&#xD;
&#xD;
          6. Not taking edaravone or on a maintenance cycle for at least 30 days prior to Screening&#xD;
             and throughout the study&#xD;
&#xD;
          7. For females of childbearing potential, a negative urine pregnancy test at Screening&#xD;
             and on Day 0&#xD;
&#xD;
          8. Male Participants and their female partners must agree to use double-barrier&#xD;
             contraception during the study or provide proof of postmenopausal state (minimum 1&#xD;
             year) or surgical sterility&#xD;
&#xD;
          9. Male Participants must not donate sperm during the study&#xD;
&#xD;
         10. Female Participants must be nonpregnant, nonlactating, and either postmenopausal for&#xD;
             at least 1 year, or surgically sterile for at least 3 months, or agree to use&#xD;
             double-barrier contraception from 28 days prior to randomization (Day 0) and/or their&#xD;
             last confirmed menstrual period prior to study randomization (whichever is longer)&#xD;
             until the end of the study&#xD;
&#xD;
         11. Capable of complying and willing to comply with the requirements and restrictions in&#xD;
             the informed consent form and this protocol&#xD;
&#xD;
         12. Willing to forgo new experimental ALS treatments for at least 6 months following&#xD;
             randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Progressive or degenerative neurological disorder such as Alzheimer's disease,&#xD;
             Parkinson's disease, vascular dementia, multiple sclerosis, and other neurological or&#xD;
             vascular disorders felt by the Investigator to preclude participation&#xD;
&#xD;
          2. Requires tracheotomy ventilation or noninvasive ventilation related to bulbar function&#xD;
&#xD;
          3. Evidence by physical examination, history, or laboratory evaluation of significant&#xD;
             concomitant disease with a life expectancy of &lt; 6 months at Screening&#xD;
&#xD;
          4. INR values &gt;2.0&#xD;
&#xD;
          5. Platelet count &lt;100,000/µL&#xD;
&#xD;
          6. Inflammatory disorder of the blood vessels (inflammatory angiopathy or vasculitis,&#xD;
             such as Buerger's disease)&#xD;
&#xD;
          7. Active infection (chronic infection or severe active infection that may compromise the&#xD;
             Participant's wellbeing or participation in the study in the Investigator's judgment)&#xD;
&#xD;
          8. Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis)&#xD;
&#xD;
          9. Positive human immunodeficiency virus (HIV) or human T-cell lymphotrophic virus (HTLV)&#xD;
             I/II test at Screening&#xD;
&#xD;
         10. Active acute or chronic hepatitis B&#xD;
&#xD;
         11. Active hepatitis C&#xD;
&#xD;
         12. Immunosuppression due to underlying disease (e.g., rheumatoid arthritis, systemic&#xD;
             lupus erythematosus) or to currently receiving immunosuppressive drugs, (e.g.,&#xD;
             chemotherapy, corticosteroids) or to radiation therapy&#xD;
&#xD;
         13. Stroke or myocardial infarction within 3 months prior to Screening&#xD;
&#xD;
         14. Active deep vein thrombosis&#xD;
&#xD;
         15. Recent history (&lt; 3 years) or presence of cancer except basal cell carcinoma or&#xD;
             squamous cell carcinoma of the skin that was excised and has shown no evidence of&#xD;
             recurrence for at least 1 year&#xD;
&#xD;
         16. Major psychiatric disorder diagnosed in the past 6 months that has not been stabilized&#xD;
             or in the Investigator's opinion would not allow the patient to participate in the&#xD;
             scheduled procedures&#xD;
&#xD;
         17. Use of an investigational drug for the treatment of ALS in the past 30 days or 5&#xD;
             half-lives (if available), whichever is longer, or previous participation in a&#xD;
             clinical study with Engensis&#xD;
&#xD;
         18. Stem cell administration for investigational treatment of ALS or other conditions in&#xD;
             the 6 months prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Guzman</last_name>
    <phone>858-428-1225</phone>
    <email>ClinicalTrials@Helixmith.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center, Barrows Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Duncan</last_name>
      <phone>602-406-1466</phone>
      <email>jessie.duncan@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Shafeeq Ladha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Joslin</last_name>
      <phone>312-503-7504</phone>
      <email>ben.joslin@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Senda Ajroud-Driss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Department of Neurology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Mosmiller</last_name>
      <phone>410-502-0495</phone>
      <email>emosmil1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Maragakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Neuromuscular Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Chiodo</last_name>
      <phone>512-920-0140</phone>
      <phone_ext>210</phone_ext>
      <email>michael@austinneuromuscle.com</email>
    </contact>
    <investigator>
      <last_name>Yessar Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bugyeong Son</last_name>
      <phone>82-2-2290-9367</phone>
      <email>sonbugyeong@hanyang.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung Hyun Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

